Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer

Published:2024-09 Issue: Volume:209 Page:114183
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Roubaud Guilhem,Attard Gerhardt,Boegemann Martin,Olmos David,Trevisan Marco,Antoni Laurent,Pascoe Katie,Capone Camille,Van Sanden Suzy,Hashim Mahmoud,Palmer Stephen,Chi Kim

Funder

Janssen Pharmaceutica

Publisher

Elsevier BV

Reference28 articles.

1. Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC);Henríquez;Biomedicines,2021

2. Overall survival and second primary malignancies in men with metastatic prostate cancer;Mehtälä;PloS One,2020

3. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes;Olmos;Ann Oncol,2024

4. Metastatic bone disease: clinical features, pathophysiology and treatment strategies;Coleman;Cancer Treat Rev,2001

5. Symptoms and impacts in metastatic castration-resistant prostate cancer: qualitative findings from patient and physician interviews;Holmstrom;Patient-Patient-Cent Outcomes Res,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP